StockData
Teva Pharmaceutical Industries Ltd logo

Teva Pharmaceutical Industries Ltd

TEVANYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/30128% above fair value
$42.62+0.05 (+0.12%)

Close on Nov 17, 2026Market cap $49.66BP/E 71.0Yield –

Teva Pharmaceutical Industries Teva API Third-Party Sales by Quarter

Teva API Third-Party Sales — Local Currency YoY Change (%)

Teva Pharmaceutical Industries Teva API Third-Party Sales: -8.0% in Q3 2026, down 4.0 pts from a year earlier.

Latest, Q3 2026
-8.0%
Period ended Sep 30, 2026
Change on a year earlier
-4.0 pts
-4.0% in Q3 2025
History
16 quarters
Since Q1 2022
Sources
16
Documents cited below

Where the Q3 2026 figure comes from

“API sales to third parties in the third quarter of 2026 were $115 million, a decrease of 8% in both U.S. dollars and local currency terms, compared to the third quarter of 2025. This decrease was mainly due to lower dema”

Source: Form 8-K Earnings Release (0001171843-26-007054) ↗

Reported in SEC Form 10-K / Form 10-Q / Form 8-K Earnings Releases.

quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedTeva API Third-Party Sales — Local Currency YoY Change (%)Year on yearSource
Q3 2026Sep 30, 2026-8.0%-4.0 ptsForm 8-K Earnings Release (0001171843-26-007054) ↗
Q2 2026Jun 30, 2026-12.0%-1.0 ptsForm 8-K Earnings Release (0001171843-26-004974) ↗
Q1 2026Mar 31, 2026-17.0%-19.0 ptsForm 8-K Earnings Release (0001171843-26-002796) ↗
Q4 2025Dec 31, 2025-4.0%–Form 8-K Earnings Release (0001171843-26-000462) ↗
Q3 2025Sep 30, 2025-4.0%-8.0 ptsForm 10-Q (0001193125-25-266895) ↗
Q2 2025Jun 30, 2025-11.0%-16.0 ptsForm 8-K Earnings Release (0001171843-25-004808) ↗
Q1 2025Mar 31, 20252.0%0.0 ptsForm 8-K Earnings Release (0001171843-25-002849) ↗
Q3 2024Sep 30, 20244.0%+16.0 ptsForm 8-K Earnings Release (0001171843-24-006034) ↗
Q2 2024Jun 30, 20245.0%+19.0 ptsForm 8-K Earnings Release (0001171843-24-004270) ↗
Q1 2024Mar 31, 20242.0%+29.0 ptsForm 10-Q (0001193125-24-134200) ↗
Q3 2023Sep 30, 2023-12.0%-5.0 ptsForm 10-Q (0001193125-23-274495) ↗
Q2 2023Jun 30, 2023-14.0%-3.0 ptsForm 8-K Earnings Release (0001193125-23-201707) ↗
Q1 2023Mar 31, 2023-27.0%-29.0 ptsForm 10-Q (0001193125-23-140697) ↗
Q3 2022Sep 30, 2022-7.0%–Form 10-Q (0001193125-22-276883) ↗
Q2 2022Jun 30, 2022-11.0%–Form 10-Q (0001193125-22-203392) ↗
Q1 2022Mar 31, 20222.0%–Form 10-Q (0001193125-22-138669) ↗

Cite this data

StockData. (2026). Teva Pharmaceutical Industries Teva API Third-Party Sales (%), quarterly Q1 2022–Q3 2026 [Data set]. Compiled from Teva Pharmaceutical Industries SEC filings and investor materials. https://stockdatahq.com/stocks/teva/kpis/sub-tapi-yoy-lc

See every metric in the Teva Pharmaceutical Industries KPI table. Data updated Nov 10, 2026.

See a number that looks wrong?